A Phase II trial of guadecitabine (G) plus atezolizumab (A) in patients with metastatic urothelial carcinoma (UC) progressing after initial checkpoint inhibitor therapy.

被引：0
|
作者：
Plimack, Elizabeth R. [1 ]
Campbell, Kerry [1 ]
Issa, Jean-Pierre J. [2 ]
Hahn, Noah M. [3 ]
Quinn, David I. [4 ]
Jang, Hyo Sik [5 ]
Hostetter, Galen [5 ]
Nichols, Peter W. [4 ]
Chung, Woonbok [2 ]
Madzo, Jozef [2 ]
Ohtani, Hitoshi [5 ]
Shen, Hui [5 ]
Hinoue, Toshinori [5 ]
Baylin, Stephen B. [3 ]
Jones, Peter A. [5 ]
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Coriell Inst Med Res, Camden, NJ USA
[3] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Van Andel Res Inst, Grand Rapids, MI USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT121
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial
    Oria, G. A. De Velasco
    Garcia-Carbonero, I.
    Esteban-Gonzalez, E.
    Pinto, A.
    Lorente, D.
    De Liano, A. Gomez
    Ortega, E. Martinez
    Colomo, L. Jimenez
    Puente, J.
    Gonzalez, I.
    Fernandez, O.
    Anguera, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1333 - S1333
  • [42] Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
    Drakaki, Alexandra
    Powles, Thomas
    Bamias, Aristotelis
    Martin-Liberal, Juan
    Shin, Sang Joon
    Friedlander, Terence
    Tosi, Diego
    Park, Chandler
    Gomez-Roca, Carlos
    Lobbedez, Florence Joly
    Castellano, Daniel
    Morales-Barrera, Rafael
    Moreno-Candilejo, Irene
    Flechon, Aude
    Yuen, Kobe
    Rishipathak, Deepali
    Dupree, Kelly
    Young, Fiona
    Michielin, Francesca
    Shemesh, Colby S.
    Steinberg, Elizabeth E.
    Williams, Patrick
    Lee, Jae Lyun
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4373 - 4384
  • [43] The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
    Tsung-Han Tsai
    Po-Jung Su
    Shih-Yu Huang
    Ming-Chun Kuo
    Chang-Ting Lin
    Chia-Che Wu
    Hao-Lun Luo
    Chien-Hsu Chen
    Chih-Chi Chou
    Ting-Ting Liu
    Chun-Chieh Huang
    Kai-Lung Tsai
    Yu-Li Su
    BMC Cancer, 23 (1)
  • [44] Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
    O'Connell, Casey L.
    Kropf, Patricia L.
    Punwani, Nathan
    Rogers, Dan
    Sposto, Richard
    Gronbaek, Kirsten
    BLOOD, 2018, 132
  • [45] The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
    Tsai, Tsung-Han
    Su, Po-Jung
    Huang, Shih-Yu
    Kuo, Ming-Chun
    Lin, Chang-Ting
    Wu, Chia-Che
    Luo, Hao-Lun
    Chen, Chien-Hsu
    Chou, Chih-Chi
    Liu, Ting-Ting
    Huang, Chun-Chieh
    Tsai, Kai-Lung
    Su, Yu-Li
    BMC CANCER, 2023, 23 (01)
  • [46] Phase II trial of palbociclib (PD-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy.
    Rose, Tracy Lynn
    Chism, David D.
    Alva, Ajjai Shivaram
    Deal, Allison Mary
    Maygarden, Susan
    Whang, Young E.
    Kardos, Jordan
    Drier, Anthony
    Kim, William Y.
    Milowsky, Matthew I.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [47] A phase II trial of chemotherapy plus hormone therapy as initial treatment of unresectable/metastatic adenocarcinoma of the prostate
    Amato, Robert J.
    Jac, Jaroslaw
    Stepankiw, Mika
    Ramirez, Perla
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [48] A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma
    Pachynski, Russell Kent
    Chatta, Gurkamal S.
    Jain, Rohit K.
    Moon, Helen H.
    Sweis, Randy F.
    Delacroix, Scott Edward
    Fang, Alana
    D'amico, Leonard A.
    Kask, Angela Shaulov
    Fling, Steven P.
    Lacroix, Andreanne
    Kaiser, Judith C.
    Sharon, Elad
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 628 - 628
  • [49] A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations
    Lee, Hye Won
    Sa, Jason K.
    Gualberto, Antonio
    Scholz, Catherine
    Sung, Hyun Hwan
    Jeong, Byong Chang
    Choi, Han Yong
    Kwon, Ghee Young
    Park, Se Hoon
    CLINICAL CANCER RESEARCH, 2020, 26 (19) : 5113 - 5119
  • [50] Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.
    Nagar, Himanshu
    Ballman, Karla V.
    Tagawa, Scott T.
    Tan, Alan
    Faltas, Bishoy Morris
    Sheybani, Arshin
    Baghaie, Shiva
    Schwartz, Lawrence Howard
    Kozono, David E.
    Bogart, Jeffrey A.
    Conway, Olivia
    Mazza, Gina L.
    Chen, Ronald C.
    Laccetti, Andrew Leonard
    Rosenberg, Jonathan E.
    Morris, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345